Original Article

 

1. Calponin and h-caldesmon expression in atypical fibroxanthoma and superficial leiomyosarcoma.

Sakamoto A, Oda Y, Yamamoto H, Oshiro Y, Miyajima K, Itakura E, Tamiya S, Honda Y, Ishihara A, Iwamoto Y, Tsuneyoshi M.

Virchows Arch. 2002 Apr;440(4):404-9. doi: 10.1007/s004280100521. Epub 2001 Nov 7.PMID: 11956822

 

2. PTEN/MMAC1 gene mutation is a rare event in soft tissue sarcomas without specific balanced translocations.

Saito T, Oda Y, Kawaguchi K, Takahira T, Yamamoto H, Tamiya S, Tanaka K, Matsuda S, Sakamoto A, Iwamoto Y, Tsuneyoshi M.

Int J Cancer. 2003 Mar 20;104(2):175-8. doi: 10.1002/ijc.10918.PMID: 12569572

 

3. Mucinous cystic tumor of the pancreas: immunohistochemical assessment of "ovarian-type stroma".

Izumo A, Yamaguchi K, Eguchi T, Nishiyama K, Yamamoto H, Yonemasu H, Yao T, Tanaka M, Tsuneyoshi M.

Oncol Rep. 2003 May-Jun;10(3):515-25.PMID: 12684617

 

4. p53 Mutation and MDM2 amplification in inflammatory myofibroblastic tumours.

Yamamoto H, Oda Y, Saito T, Sakamoto A, Miyajima K, Tamiya S, Tsuneyoshi M.

Histopathology. 2003 May;42(5):431-9. doi: 10.1046/j.1365-2559.2003.01611.x.PMID: 12713619

 

5. Possible association between tumor-suppressor gene mutations and hMSH2/hMLH1 inactivation in alveolar soft part sarcoma.

Saito T, Oda Y, Kawaguchi K, Takahira T, Yamamoto H, Sakamoto A, Tamiya S, Iwamoto Y, Tsuneyoshi M.

Hum Pathol. 2003 Sep;34(9):841-9. doi: 10.1016/s0046-8177(03)00343-5.PMID: 14562278

 

6. Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis.

Kawaguchi K, Oda Y, Saito T, Yamamoto H, Tamiya S, Takahira T, Miyajima K, Iwamoto Y, Tsuneyoshi M.

J Pathol. 2003 Nov;201(3):487-95. doi: 10.1002/path.1419.PMID: 14595762

 

7. Altered expression of cell cycle regulators in myxofibrosarcoma, with special emphasis on their prognostic implications.

Oda Y, Takahira T, Kawaguchi K, Yamamoto H, Tamiya S, Matsuda S, Tanaka K, Kinukawa N, Iwamoto Y, Tsuneyoshi M.

Hum Pathol. 2003 Oct;34(10):1035-42. doi: 10.1053/s0046-8177(03)00404-0.PMID: 14608538

 

8. Decreased expression of transforming growth factor-beta II receptor is associated with that of p27KIP1 in giant cell tumor of bone: a possible link between transforming growth factor-beta and cell cycle-related protein.

Kawaguchi K, Oda Y, Saito T, Yamamoto H, Takahira T, Tamiya S, Iwamoto Y, Tsuneyoshi M.

Hum Pathol. 2004 Jan;35(1):61-8. doi: 10.1016/j.humpath.2003.07.004.PMID: 14745726

 

9. Low-grade fibromyxoid sarcoma versus low-grade myxofibrosarcoma in the extremities and trunk. A comparison of clinicopathological and immunohistochemical features.

Oda Y, Takahira T, Kawaguchi K, Yamamoto H, Tamiya S, Matsuda S, Tanaka K, Iwamoto Y, Tsuneyoshi M.

Histopathology. 2004 Jul;45(1):29-38. doi: 10.1111/j.1365-2559.2004.01886.x.

PMID: 15228441

 

10. H-ras mutation is an additional event of sarcomatous transformation in aerodigestive spindle cell carcinoma.

Shiratsuchi H, Hirakawa N, Saito T, Oda Y, Yamamoto H, Tomita K, Yamamoto T, Tsuneyoshi M.

Oncol Rep. 2004 Mar;11(3):597-604.

PMID: 14767509

 

11. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis.

Kuwano T, Nakao S, Yamamoto H, Tsuneyoshi M, Yamamoto T, Kuwano M, Ono M.

FASEB J. 2004 Feb;18(2):300-10. doi: 10.1096/fj.03-0473com.PMID: 14769824

 

12. Microsatellite instability and p53 mutation associated with tumor progression in dermatofibrosarcoma protuberans.

Takahira T, Oda Y, Tamiya S, Yamamoto H, Kawaguchi K, Kobayashi C, Oda S, Iwamoto Y, Tsuneyoshi M.

Hum Pathol. 2004 Feb;35(2):240-5. doi: 10.1016/j.humpath.2003.09.016.PMID: 14991543

 

13. PTEN and other tumor suppressor gene mutations as secondary genetic alterations in synovial sarcoma.

Saito T, Oda Y, Kawaguchi K, Takahira T, Yamamoto H, Tanaka K, Matsuda S, Sakamoto A, Iwamoto Y, Tsuneyoshi M.

Oncol Rep. 2004 May;11(5):1011-5.PMID: 15069540

 

14. c-kit and PDGFRA mutations in extragastrointestinal stromal tumor (gastrointestinal stromal tumor of the soft tissue).

Yamamoto H, Oda Y, Kawaguchi K, Nakamura N, Takahira T, Tamiya S, Saito T, Oshiro Y, Ohta M, Yao T, Tsuneyoshi M.

Am J Surg Pathol. 2004 Apr;28(4):479-88. doi: 10.1097/00000478-200404000-00007.PMID: 15087667

 

15. Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma.

Takahashi Y, Oda Y, Kawaguchi K, Tamiya S, Yamamoto H, Suita S, Tsuneyoshi M.

Mod Pathol. 2004 Jun;17(6):660-9. doi: 10.1038/modpathol.3800101.

PMID: 15098008

 

16. Alterations of the p16INK4a/p14ARF pathway in clear cell sarcoma.

Takahira T, Oda Y, Tamiya S, Yamamoto H, Kawaguchi K, Kobayashi C, Iwamoto Y, Tsuneyoshi M.

Cancer Sci. 2004 Aug;95(8):651-5. doi: 10.1111/j.1349-7006.2004.tb03324.x.PMID: 15298727

 

17. E-cadherin mutation and Snail overexpression as alternative mechanisms of E-cadherin inactivation in synovial sarcoma.

Saito T, Oda Y, Kawaguchi K, Sugimachi K, Yamamoto H, Tateishi N, Tanaka K, Matsuda S, Iwamoto Y, Ladanyi M, Tsuneyoshi M.

Oncogene. 2004 Nov 11;23(53):8629-38. doi: 10.1038/sj.onc.1207960.PMID: 15467754

 

18. Death-associated protein kinase (DAP kinase) alteration in soft tissue leiomyosarcoma: Promoter methylation or homozygous deletion is associated with a loss of DAP kinase expression.

Kawaguchi K, Oda Y, Saito T, Yamamoto H, Takahira T, Tamiya S, Iwamoto Y, Tsuneyoshi M.

Hum Pathol. 2004 Oct;35(10):1266-71. doi: 10.1016/j.humpath.2004.07.007.PMID: 15492995

 

19. ATP-binding cassette superfamily transporter gene expression in human soft tissue sarcomas.

Oda Y, Saito T, Tateishi N, Ohishi Y, Tamiya S, Yamamoto H, Yokoyama R, Uchiumi T, Iwamoto Y, Kuwano M, Tsuneyoshi M.

Int J Cancer. 2005 May 10;114(6):854-62. doi: 10.1002/ijc.20589.PMID: 15609299

 

20. Microsatellite instability and hMLH1 and hMSH2 expression analysis in soft tissue sarcomas.

Kawaguchi K, Oda Y, Takahira T, Saito T, Yamamoto H, Kobayashi C, Tamiya S, Oda S, Iwamoto Y, Tsuneyoshi M.

Oncol Rep. 2005 Feb;13(2):241-6.PMID: 15643505

 

21. Genetic and epigenetic alterations of the PTEN gene in soft tissue sarcomas.

Kawaguchi K, Oda Y, Saito T, Takahira T, Yamamoto H, Tamiya S, Iwamoto Y, Tsuneyoshi M.

Hum Pathol. 2005 Apr;36(4):357-63. doi: 10.1016/j.humpath.2005.01.017.PMID: 15891996

 

22. Alterations of the RB1 gene in dedifferentiated liposarcoma.

Takahira T, Oda Y, Tamiya S, Yamamoto H, Kobayashi C, Izumi T, Ito K, Iwamoto Y, Tsuneyoshi M.

Mod Pathol. 2005 Nov;18(11):1461-70. doi: 10.1038/modpathol.3800447.PMID: 15933756

 

23. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade.

Nakamura N, Yamamoto H, Yao T, Oda Y, Nishiyama K, Imamura M, Yamada T, Nawata H, Tsuneyoshi M.

Hum Pathol. 2005 Jul;36(7):828-37. doi: 10.1016/j.humpath.2005.03.012.PMID: 16084954

 

24. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis.

Oda Y, Yamamoto H, Takahira T, Kobayashi C, Kawaguchi K, Tateishi N, Nozuka Y, Tamiya S, Tanaka K, Matsuda S, Yokoyama R, Iwamoto Y, Tsuneyoshi M.

J Pathol. 2005 Dec;207(4):410-21. doi: 10.1002/path.1848.PMID: 16177957

 

25. Microsatellite instability and proliferating activity in sinonasal carcinoma: molecular genetic and immunohistochemical comparison with oral squamous cell carcinoma.

Uryu H, Oda Y, Shiratsuchi H, Oda S, Yamamoto H, Komune S, Tsuneyoshi M.

Oncol Rep. 2005 Nov;14(5):1133-42.PMID: 16211276

 

26. DNA hypermethylation status of multiple genes in soft tissue sarcomas.

Kawaguchi K, Oda Y, Saito T, Yamamoto H, Takahira T, Kobayashi C, Tamiya S, Tateishi N, Iwamoto Y, Tsuneyoshi M.

Mod Pathol. 2006 Jan;19(1):106-14. doi: 10.1038/modpathol.3800502.PMID: 16258501

 

27. Chromosomal aberrations and microsatellite instability of malignant peripheral nerve sheath tumors: a study of 10 tumors from nine patients.

Kobayashi C, Oda Y, Takahira T, Izumi T, Kawaguchi K, Yamamoto H, Tamiya S, Yamada T, Oda S, Tanaka K, Matsuda S, Iwamoto Y, Tsuneyoshi M.

Cancer Genet Cytogenet. 2006 Mar;165(2):98-105. doi: 10.1016/j.cancergencyto.2005.07.006.PMID: 16527603

 

28. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis.

Oda Y, Yamamoto H, Tamiya S, Matsuda S, Tanaka K, Yokoyama R, Iwamoto Y, Tsuneyoshi M.

Mod Pathol. 2006 May;19(5):738-45. doi: 10.1038/modpathol.3800587.PMID: 16528367

 

29. Aberrant expression of CHFR in malignant peripheral nerve sheath tumors.

Kobayashi C, Oda Y, Takahira T, Izumi T, Kawaguchi K, Yamamoto H, Tamiya S, Yamada T, Iwamoto Y, Tsuneyoshi M.

Mod Pathol. 2006 Apr;19(4):524-32. doi: 10.1038/modpathol.3800548.PMID: 16554732

 

30. Prognostic significance of dysadherin expression in epithelioid sarcoma and its diagnostic utility in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.

Izumi T, Oda Y, Hasegawa T, Nakanishi Y, Iwasaki H, Sonobe H, Goto H, Kusakabe H, Takahira T, Kobayashi C, Kawaguchi K, Saito T, Yamamoto H, Tamiya S, Iwamoto Y, Tsuneyoshi M.

Mod Pathol. 2006 Jun;19(6):820-31. doi: 10.1038/modpathol.3800599.PMID: 16557275

 

31. Nuclear beta-catenin correlates with cyclin D1 expression in spindle and pleomorphic sarcomas but not in synovial sarcoma.

Saito T, Oda Y, Yamamoto H, Kawaguchi K, Tanaka K, Matsuda S, Iwamoto Y, Tsuneyoshi M.

Hum Pathol. 2006 Jun;37(6):689-97. doi: 10.1016/j.humpath.2006.01.017.PMID: 16733209

 

32. Absence of human herpesvirus-8 and Epstein-Barr virus in inflammatory myofibroblastic tumor with anaplastic large cell lymphoma kinase fusion gene.

Yamamoto H, Kohashi K, Oda Y, Tamiya S, Takahashi Y, Kinoshita Y, Ishizawa S, Kubota M, Tsuneyoshi M.

Pathol Int. 2006 Oct;56(10):584-90. doi: 10.1111/j.1440-1827.2006.02012.x.PMID: 16984614

 

33. Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: special reference to its inverse relationship with E-cadherin expression.

Izumi T, Oda Y, Hasegawa T, Nakanishi Y, Kawai A, Sonobe H, Takahira T, Kobayashi C, Yamamoto H, Tamiya S, Hirohashi S, Iwamoto Y, Tsuneyoshi M.

Am J Surg Pathol. 2007 Jan;31(1):85-94. doi: 10.1097/01.pas.0000213413.33558.85.PMID: 17197923

 

34. Prognostic significance of angiogenesis in gastrointestinal stromal tumor.

Imamura M, Yamamoto H, Nakamura N, Oda Y, Yao T, Kakeji Y, Baba H, Maehara Y, Tsuneyoshi M.

Mod Pathol. 2007 May;20(5):529-37. doi: 10.1038/modpathol.3800767. Epub 2007 Mar 2.PMID: 17334345

 

35. Detection of COL1A1-PDGFB fusion transcripts and PDGFB/PDGFRB mRNA expression in dermatofibrosarcoma protuberans.

Takahira T, Oda Y, Tamiya S, Higaki K, Yamamoto H, Kobayashi C, Izumi T, Tateishi N, Iwamoto Y, Tsuneyoshi M.

Mod Pathol. 2007 Jun;20(6):668-75. doi: 10.1038/modpathol.3800783. Epub 2007 Apr 13.PMID: 17431412

 

36. Highly aggressive behavior of malignant rhabdoid tumor: a special reference to SMARCB1/INI1 gene alterations using molecular genetic analysis including quantitative real-time PCR.

Kohashi K, Oda Y, Yamamoto H, Tamiya S, Izumi T, Ohta S, Taguchi T, Suita S, Tsuneyoshi M.

J Cancer Res Clin Oncol. 2007 Nov;133(11):817-24. doi: 10.1007/s00432-007-0223-z. Epub 2007 May 8.PMID: 17486366

 

37. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas.

Itakura E, Yamamoto H, Oda Y, Tsuneyoshi M.

J Surg Oncol. 2008 Jan 1;97(1):74-81. doi: 10.1002/jso.20766.PMID: 18041747

 

38. Overexpression of inducible nitric oxide synthase and accumulation of 8-OHdG in nasopharyngeal carcinoma.

Segawa Y, Oda Y, Yamamoto H, Uryu H, Shiratsuchi H, Hirakawa N, Tomita K, Yamamoto T, Oda S, Yamada T, Komune S, Tsuneyoshi M.

Histopathology. 2008 Jan;52(2):213-23. doi: 10.1111/j.1365-2559.2007.02920.x.

PMID: 18184270

 

39. Different expression profiles of Y-box-binding protein-1 and multidrug resistance-associated proteins between alveolar and embryonal rhabdomyosarcoma.

Oda Y, Kohashi K, Yamamoto H, Tamiya S, Kohno K, Kuwano M, Iwamoto Y, Tajiri T, Taguchi T, Tsuneyoshi M.

Cancer Sci. 2008 Apr;99(4):726-32. doi: 10.1111/j.1349-7006.2008.00748.x.PMID: 18377424

 

40. Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype.

Kohashi K, Oda Y, Yamamoto H, Tamiya S, Takahira T, Takahashi Y, Tajiri T, Taguchi T, Suita S, Tsuneyoshi M.

J Cancer Res Clin Oncol. 2008 Oct;134(10):1097-103. doi: 10.1007/s00432-008-0385-3. Epub 2008 Apr 2.PMID: 18386058

 

41. SMARCB1/INI1 protein expression in round cell soft tissue sarcomas associated with chromosomal translocations involving EWS: a special reference to SMARCB1/INI1 negative variant extraskeletal myxoid chondrosarcoma.

Kohashi K, Oda Y, Yamamoto H, Tamiya S, Oshiro Y, Izumi T, Taguchi T, Tsuneyoshi M.

Am J Surg Pathol. 2008 Aug;32(8):1168-74. doi: 10.1097/PAS.0b013e318161781a.PMID: 18580682

 

42. Correlation between beta-catenin widespread nuclear expression and matrix metalloproteinase-7 overexpression in sporadic desmoid tumors.

Matono H, Oda Y, Nakamori M, Tamiya S, Yamamoto H, Yokoyama R, Saito T, Iwamoto Y, Tsuneyoshi M.

Hum Pathol. 2008 Dec;39(12):1802-8. doi: 10.1016/j.humpath.2008.05.005. Epub 2008 Aug 19.PMID: 18715618

 

43. Enhanced mass on contrast-enhanced breast MR imaging: Lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images.

Yabuuchi H, Matsuo Y, Okafuji T, Kamitani T, Soeda H, Setoguchi T, Sakai S, Hatakenaka M, Kubo M, Sadanaga N, Yamamoto H, Honda H.

J Magn Reson Imaging. 2008 Nov;28(5):1157-65. doi: 10.1002/jmri.21570.PMID: 18972357

 

44. Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.

Kohashi K, Izumi T, Oda Y, Yamamoto H, Tamiya S, Taguchi T, Iwamoto Y, Hasegawa T, Tsuneyoshi M.

Hum Pathol. 2009 Mar;40(3):349-55. doi: 10.1016/j.humpath.2008.08.007. Epub 2008 Oct 29.PMID: 18973917

 

45. Circumscribed mass lesions on mammography: dynamic contrast-enhanced MR imaging to differentiate malignancy and benignancy.

Okafuji T, Yabuuchi H, Soeda H, Matsuo Y, Kamitani T, Sakai S, Hatakenaka M, Kuroki S, Tokunaga E, Yamamoto H, Honda H.

Magn Reson Med Sci. 2008;7(4):195-204. doi: 10.2463/mrms.7.195.PMID: 19110514

 

46. Neurofibromatosis type 1-related gastrointestinal stromal tumors: a special reference to loss of heterozygosity at 14q and 22q.

Yamamoto H, Tobo T, Nakamori M, Imamura M, Kojima A, Oda Y, Nakamura N, Takahira T, Yao T, Tsuneyoshi M.

J Cancer Res Clin Oncol. 2009 Jun;135(6):791-8. doi: 10.1007/s00432-008-0514-z. Epub 2008 Nov 20.PMID: 19020900

 

47. VEGF-C and VEGFR-3 in a series of lymphangiomas: is superficial lymphangioma a true lymphangioma?

Itakura E, Yamamoto H, Oda Y, Furue M, Tsuneyoshi M.

Virchows Arch. 2009 Mar;454(3):317-25. doi: 10.1007/s00428-008-0720-8. Epub 2009 Jan 17.PMID: 19151999

 

48. Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma.

Oda Y, Tateishi N, Matono H, Matsuura S, Yamamaoto H, Tamiya S, Yokoyama R, Matsuda S, Iwamoto Y, Tsuneyoshi M.

Int J Cancer. 2009 Apr 15;124(8):1852-9. doi: 10.1002/ijc.24128.

PMID: 19107931

 

49. Close correlation between CXCR4 and VEGF expression and their prognostic implications in nasopharyngeal carcinoma.

Segawa Y, Oda Y, Yamamoto H, Shiratsuchi H, Hirakawa N, Komune S, Tsuneyoshi M.

Oncol Rep. 2009 May;21(5):1197-202. doi: 10.3892/or_00000341.PMID: 19360294

 

50. Inflammatory myofibroblastic tumor versus IgG4-related sclerosing disease and inflammatory pseudotumor: a comparative clinicopathologic study.

Yamamoto H, Yamaguchi H, Aishima S, Oda Y, Kohashi K, Oshiro Y, Tsuneyoshi M.

Am J Surg Pathol. 2009 Sep;33(9):1330-40. doi: 10.1097/pas.0b013e3181a5a207.PMID: 19718789

 

51. Non-mass-like enhancement on contrast-enhanced breast MR imaging: lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images.

Yabuuchi H, Matsuo Y, Kamitani T, Setoguchi T, Okafuji T, Soeda H, Sakai S, Hatakenaka M, Kubo M, Tokunaga E, Yamamoto H, Honda H.

Eur J Radiol. 2010 Jul;75(1):e126-32. doi: 10.1016/j.ejrad.2009.09.013. Epub 2009 Sep 30.PMID: 19796900

 

52. Overexpression of A disintegrin and metalloproteinase 28 is correlated with high histologic grade in conventional chondrosarcoma.

Matsuura S, Oda Y, Matono H, Izumi T, Yamamoto H, Tamiya S, Iwamoto Y, Tsuneyoshi M.

Hum Pathol. 2010 Mar;41(3):343-51. doi: 10.1016/j.humpath.2009.08.002. Epub 2009 Nov 7.PMID: 19896699

 

53. Down-regulation of artery in moderately differentiated hepatocellular carcinoma related to tumor development.

Fujita N, Aishima S, Iguchi T, Nishihara Y, Yamamoto H, Taketomi A, Oda Y, Honda H, Tsuneyoshi M.

Hum Pathol. 2010 Jun;41(6):838-47. doi: 10.1016/j.humpath.2009.11.011. Epub 2010 Feb 25.PMID: 20185161

 

54. Reduced expression of SMARCB1/INI1 protein in synovial sarcoma.

Kohashi K, Oda Y, Yamamoto H, Tamiya S, Matono H, Iwamoto Y, Taguchi T, Tsuneyoshi M.

Mod Pathol. 2010 Jul;23(7):981-90. doi: 10.1038/modpathol.2010.71. Epub 2010 Mar 19.PMID: 20305614

 

55. Prognostic impact of blood vessel invasion in gastrointestinal stromal tumor of the stomach.

Yamamoto H, Kojima A, Miyasaka Y, Imamura M, Nakamura N, Yao T, Tsuneyoshi M, Oda Y.

Hum Pathol. 2010 Oct;41(10):1422-30. doi: 10.1016/j.humpath.2010.02.013. Epub 2010 Jun 22.PMID: 20573370

 

56. Mucin core protein expression in serrated polyps of the large intestine.

Fujita K, Hirahashi M, Yamamoto H, Matsumoto T, Gushima M, Oda Y, Kishimoto J, Yao T, Iida M, Tsuneyoshi M.

Virchows Arch. 2010 Oct;457(4):443-9. doi: 10.1007/s00428-010-0959-8. Epub 2010 Aug 28.PMID: 20803031

 

57. Detection of non-palpable breast cancer in asymptomatic women by using unenhanced diffusion-weighted and T2-weighted MR imaging: comparison with mammography and dynamic contrast-enhanced MR imaging.

Yabuuchi H, Matsuo Y, Sunami S, Kamitani T, Kawanami S, Setoguchi T, Sakai S, Hatakenaka M, Kubo M, Tokunaga E, Yamamoto H, Honda H.

Eur Radiol. 2011 Jan;21(1):11-7. doi: 10.1007/s00330-010-1890-8. Epub 2010 Jul 18.PMID: 20640898

 

58. Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors.

Endo M, Kobayashi C, Setsu N, Takahashi Y, Kohashi K, Yamamoto H, Tamiya S, Matsuda S, Iwamoto Y, Tsuneyoshi M, Oda Y.

Clin Cancer Res. 2011 Jun 1;17(11):3771-82. doi: 10.1158/1078-0432.CCR-10-2393. Epub 2011 Jan 24.PMID: 21262917

 

59. Sessile serrated adenoma with early neoplastic progression: a clinicopathologic and molecular study.

Fujita K, Yamamoto H, Matsumoto T, Hirahashi M, Gushima M, Kishimoto J, Nishiyama K, Taguchi T, Yao T, Oda Y.

Am J Surg Pathol. 2011 Feb;35(2):295-304. doi: 10.1097/PAS.0b013e318205df36.PMID: 21263251

 

60. S100P expression in ductal type of carcinoma ex pleomorphic adenoma.

Hashimoto K, Yamamoto H, Shiratsuchi H, Nakashima T, Tamiya S, Higaki Y, Komune S, Tsuneyoshi M, Oda Y.

Am J Surg Pathol. 2011 Mar;35(3):346-55. doi: 10.1097/PAS.0b013e31820832a6.PMID: 21317706

 

61. Heterozygosity loss at 22q and lack of INI1 gene mutation in gastrointestinal stromal tumor.

Yamamoto H, Kohashi K, Tsuneyoshi M, Oda Y.

Pathobiology. 2011;78(3):132-9. doi: 10.1159/000323564. Epub 2011 May 26.PMID: 21613800

 

62. KIT-negative gastrointestinal stromal tumor of the abdominal soft tissue: a clinicopathologic and genetic study of 10 cases.

Yamamoto H, Kojima A, Nagata S, Tomita Y, Takahashi S, Oda Y.

Am J Surg Pathol. 2011 Sep;35(9):1287-95. doi: 10.1097/PAS.0b013e3182206f15.PMID: 21836495

 

63. Diagnostic performance in differentiation of breast lesion on digital mammograms: comparison among hard-copy film, 3-megapixel LCD monitor, and 5-megapixel LCD monitor.

Kamitani T, Yabuuchi H, Matsuo Y, Setoguchi T, Sakai S, Okafuji T, Sunami S, Hatakenaka M, Ishii N, Kubo M, Tokunaga E, Yamamoto H, Honda H.

Clin Imaging. 2011 Sep-Oct;35(5):341-5. doi: 10.1016/j.clinimag.2010.08.015.PMID: 21872122

 

64. The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas.

Setsu N, Yamamoto H, Kohashi K, Endo M, Matsuda S, Yokoyama R, Nishiyama K, Iwamoto Y, Dobashi Y, Oda Y.

Cancer. 2012 Mar 15;118(6):1637-48. doi: 10.1002/cncr.26448. Epub 2011 Aug 11.PMID: 21837670

 

65. Inhibin-α and synaptophysin immunoreactivity in synovial sarcoma with granular cell features.

Setsu N, Kohashi K, Endo M, Yamamoto H, Ohishi Y, Sueyoshi K, Iwamoto Y, Tsuneyoshi M, Motoi T, Kumagai A, Oda Y.

Hum Pathol. 2012 Jun;43(6):850-7. doi: 10.1016/j.humpath.2011.07.012. Epub 2011 Nov 4.PMID: 22055401

 

66. Expression level of the mitotic checkpoint protein and G2-M cell cycle regulators and prognosis in gastrointestinal stromal tumors in the stomach.

Fujita A, Yamamoto H, Imamura M, Nakamura N, Maehara Y, Tsuneyoshi M, Oda Y.

Virchows Arch. 2012 Feb;460(2):163-9. doi: 10.1007/s00428-011-1181-z. Epub 2011 Dec 22.PMID: 22190007

 

67. HER-2/neu gene amplification in carcinoma ex pleomorphic adenoma in relation to progression and prognosis: a chromogenic in-situ hybridization study.

Hashimoto K, Yamamoto H, Shiratsuchi H, Nakashima T, Tamiya S, Nishiyama K, Higaki Y, Komune S, Tsuneyoshi M, Oda Y.

Histopathology. 2012 May;60(6B):E131-42. doi: 10.1111/j.1365-2559.2012.04201.x. Epub 2012 Apr 4.PMID: 22486195

 

68. Phosphorylation of signal transducer and activator of transcription 3 in soft tissue leiomyosarcoma is associated with a better prognosis.

Setsu N, Kohashi K, Endo M, Yamamoto H, Tamiya S, Takahashi Y, Yamada Y, Ishii T, Matsuda S, Yokoyama R, Iwamoto Y, Oda Y.

Int J Cancer. 2013 Jan 1;132(1):109-15. doi: 10.1002/ijc.27655. Epub 2012 Jun 20.PMID: 22644781

 

69. Epithelial and cartilaginous differentiation in clear cell chondrosarcoma.

Matsuura S, Ishii T, Endo M, Takahashi Y, Setsu N, Yamamoto H, Tamiya S, Iwamoto Y, Oda Y.

Hum Pathol. 2013 Feb;44(2):237-43. doi: 10.1016/j.humpath.2012.05.012. Epub 2012 Aug 31.PMID: 22944296

 

70. Glypican 3 expression in tumors with loss of SMARCB1/INI1 protein expression.

Kohashi K, Nakatsura T, Kinoshita Y, Yamamoto H, Yamada Y, Tajiri T, Taguchi T, Iwamoto Y, Oda Y.

Hum Pathol. 2013 Apr;44(4):526-33. doi: 10.1016/j.humpath.2012.06.014. Epub 2012 Oct 16.PMID: 23084579

 

71. Fascin-1 overexpression and miR-133b downregulation in the progression of gastrointestinal stromal tumor.

Yamamoto H, Kohashi K, Fujita A, Oda Y.

Mod Pathol. 2013 Apr;26(4):563-71. doi: 10.1038/modpathol.2012.198. Epub 2012 Nov 30.PMID: 23196799

 

72. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.

Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T, Iida K, Matsumoto Y, Hakozaki M, Aoki M, Iwasaki H, Dobashi Y, Nishiyama K, Iwamoto Y, Oda Y.

Clin Cancer Res. 2013 Jan 15;19(2):450-61. doi: 10.1158/1078-0432.CCR-12-1067. Epub 2012 Dec 3.PMID: 23209032

 

73. Insulin-like growth factor II messenger RNA-binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm.

Morimatsu K, Aishima S, Yamamoto H, Hayashi A, Nakata K, Oda Y, Shindo K, Fujino M, Tanaka M, Oda Y.

Hum Pathol. 2013 Sep;44(9):1714-21. doi: 10.1016/j.humpath.2012.12.020. Epub 2013 Apr 15.PMID: 23597774

 

74. Clinicopathological features of primary leiomyosarcoma of the gastrointestinal tract following recognition of gastrointestinal stromal tumours.

Yamamoto H, Handa M, Tobo T, Setsu N, Fujita K, Oshiro Y, Mihara Y, Yoshikawa Y, Oda Y.

Histopathology. 2013 Aug;63(2):194-207. doi: 10.1111/his.12159. Epub 2013 Jun 13.PMID: 23763337

 

75. HER2 and EGFR gene copy number alterations are predominant in high-grade salivary mucoepidermoid carcinoma irrespective of MAML2 fusion status.

Nakano T, Yamamoto H, Hashimoto K, Tamiya S, Shiratsuchi H, Nakashima T, Nishiyama K, Higaki Y, Komune S, Oda Y.

Histopathology. 2013 Sep;63(3):378-92. doi: 10.1111/his.12183. Epub 2013 Jul 16.PMID: 23855785

 

76. Correlations between apparent diffusion coefficient values and prognostic factors of breast cancer.

Kamitani T, Matsuo Y, Yabuuchi H, Fujita N, Nagao M, Jinnouchi M, Yonezawa M, Yamasaki Y, Tokunaga E, Kubo M, Yamamoto H, Yoshiura T, Honda H.

Magn Reson Med Sci. 2013;12(3):193-9. doi: 10.2463/mrms.2012-0095. Epub 2013 Jul 12.PMID: 23857151

 

77. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma.

Setsu N, Kohashi K, Fushimi F, Endo M, Yamamoto H, Takahashi Y, Yamada Y, Ishii T, Yokoyama K, Iwamoto Y, Oda Y.

Cancer. 2013 Oct 1;119(19):3504-13. doi: 10.1002/cncr.28255. Epub 2013 Jul 16.PMID: 23861137

 

78. Differential microRNA expression profiles between malignant rhabdoid tumor and epithelioid sarcoma: miR193a-5p is suggested to downregulate SMARCB1 mRNA expression.

Kohashi K, Yamamoto H, Kumagai R, Yamada Y, Hotokebuchi Y, Taguchi T, Iwamoto Y, Oda Y.

Mod Pathol. 2014 Jun;27(6):832-9. doi: 10.1038/modpathol.2013.213. Epub 2013 Nov 29.PMID: 24287458

 

79. Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.

Yamada Y, Kohashi K, Fushimi F, Takahashi Y, Setsu N, Endo M, Yamamoto H, Tokunaga S, Iwamoto Y, Oda Y.

Cancer. 2014 Mar 15;120(6):864-76. doi: 10.1002/cncr.28506. Epub 2013 Dec 18.PMID: 24353015

 

80. Insulin-like growth factor II messenger RNA-binding protein 3 expression in gastrointestinal mesenchymal tumors.

Yamamoto H, Arakaki K, Morimatsu K, Zaitsu Y, Fujita A, Kohashi K, Hirahashi M, Motoshita J, Oshiro Y, Oda Y.

Hum Pathol. 2014 Mar;45(3):481-7. doi: 10.1016/j.humpath.2013.10.010. Epub 2013 Oct 23.PMID: 24411949

 

81. Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas.

Takahashi Y, Kohashi K, Yamada Y, Endo M, Setsu N, Ishii T, Yamamoto H, Iwamoto Y, Oda Y.

Hum Pathol. 2014 May;45(5):984-93. doi: 10.1016/j.humpath.2013.12.012. Epub 2014 Jan 8.PMID: 24746202

 

82. Differentiation between benign phyllodes tumors and fibroadenomas of the breast on MR imaging.

Kamitani T, Matsuo Y, Yabuuchi H, Fujita N, Nagao M, Kawanami S, Yonezawa M, Yamasaki Y, Tokunaga E, Kubo M, Yamamoto H, Honda H.

Eur J Radiol. 2014 Aug;83(8):1344-9. doi: 10.1016/j.ejrad.2014.04.031. Epub 2014 May 9.PMID: 24856515

 

83. Close correlation between CXCR4 and VEGF expression and frequent CXCR7 expression in rhabdomyosarcoma.

Miyoshi K, Kohashi K, Fushimi F, Yamamoto H, Kishimoto J, Taguchi T, Iwamoto Y, Oda Y.

Hum Pathol. 2014 Sep;45(9):1900-9. doi: 10.1016/j.humpath.2014.05.012. Epub 2014 Jun 12.PMID: 25086956

 

84. Hyalinizing clear cell carcinoma with EWSR1-ATF1 fusion gene: report of three cases with molecular analyses.

Nakano T, Yamamoto H, Nishijima T, Tamiya S, Shiratsuchi H, Nakashima T, Komune S, Oda Y.

Virchows Arch. 2015 Jan;466(1):37-43. doi: 10.1007/s00428-014-1676-5. Epub 2014 Oct 31.PMID: 25359601

 

85. Laparoscopic en bloc excision of gastrointestinal stromal tumors of the rectum after neoadjuvant imatinib therapy: anteriorly extended intersphincteric resection combined with partial resection of the prostate.

Ueki T, Nagayoshi K, Manabe T, Maeyama R, Yokomizo A, Yamamoto H, Oda Y, Tanaka M.

Tech Coloproctol. 2015 Apr;19(4):247-51. doi: 10.1007/s10151-014-1261-6. Epub 2014 Dec 31.PMID: 25550117

 

86. ERG and SALL4 expressions in SMARCB1/INI1-deficient tumors: a useful tool for distinguishing epithelioid sarcoma from malignant rhabdoid tumor.

Kohashi K, Yamada Y, Hotokebuchi Y, Yamamoto H, Taguchi T, Iwamoto Y, Oda Y.

Hum Pathol. 2015 Feb;46(2):225-30. doi: 10.1016/j.humpath.2014.10.010. Epub 2014 Nov 4.PMID: 25479928

 

87. Malignant solitary fibrous tumor with high-grade nuclear atypia: an alternate entity for the undetermined tumor group.

Yamada Y, Kohashi K, Bekki H, Ishii T, Iura K, Maekawa A, Yamamoto H, Iwamoto Y, Oda Y.

Pathol Res Pract. 2015 Feb;211(2):117-24. doi: 10.1016/j.prp.2014.12.002. Epub 2014 Dec 11.PMID: 25554652

 

88. Mucinous phenotype and CD10 expression of primary adenocarcinoma of the small intestine.

Kumagai R, Kohashi K, Takahashi S, Yamamoto H, Hirahashi M, Taguchi K, Nishiyama K, Oda Y.

World J Gastroenterol. 2015 Mar 7;21(9):2700-10. doi: 10.3748/wjg.v21.i9.2700.PMID: 25759539

 

89. Expression of adhesion molecules and epithelial-mesenchymal transition factors in medullary carcinoma of the colorectum.

Takahashi S, Kohashi K, Yamamoto H, Hirahashi M, Kumagai R, Takizawa N, Nakamura K, Maehara Y, Tanaka M, Takayanagi R, Oda Y.

Hum Pathol. 2015 Sep;46(9):1257-66. doi: 10.1016/j.humpath.2015.05.023. Epub 2015 Jun 10.PMID: 26208847

 

90. Dual gain of HER2 and EGFR gene copy numbers impacts the prognosis of carcinoma ex pleomorphic adenoma.

Nishijima T, Yamamoto H, Nakano T, Nakashima T, Taguchi K, Masuda M, Motoshita J, Komune S, Oda Y.

Hum Pathol. 2015 Nov;46(11):1730-43. doi: 10.1016/j.humpath.2015.07.014. Epub 2015 Jul 30.PMID: 26345124

 

91. Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic sarcoma.

Bekki H, Kohashi K, Maekawa A, Yamada Y, Yamamoto H, Harimaya K, Hakozaki M, Nabeshima K, Iwamoto Y, Oda Y.

BMC Cancer. 2015 Oct 26;15:804. doi: 10.1186/s12885-015-1830-8.PMID: 26502919

 

92. Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.

Iura K, Kohashi K, Hotokebuchi Y, Ishii T, Maekawa A, Yamada Y, Yamamoto H, Iwamoto Y, Oda Y.

J Pathol Clin Res. 2015 Mar 16;1(3):144-59. doi: 10.1002/cjp2.16. eCollection 2015 Jul.PMID: 27499900

 

93. Utility of adaptive control processing for the interpretation of digital mammograms.

Jinnouchi M, Yabuuchi H, Kubo M, Tokunaga E, Yamamoto H, Honda H.

Acta Radiol. 2016 Nov;57(11):1297-1303. doi: 10.1177/0284185115586022. Epub 2016 Jul 21.PMID: 25995309

 

94. Activation of the Akt-mTOR and MAPK pathways in dedifferentiated liposarcomas.

Ishii T, Kohashi K, Iura K, Maekawa A, Bekki H, Yamada Y, Yamamoto H, Nabeshima K, Kawashima H, Iwamoto Y, Oda Y.

Tumour Biol. 2016 Apr;37(4):4767-76. doi: 10.1007/s13277-015-4232-2. Epub 2015 Oct 30.PMID: 26518767

 

95. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.

Yamamoto H, Yoshida A, Taguchi K, Kohashi K, Hatanaka Y, Yamashita A, Mori D, Oda Y.

Histopathology. 2016 Jul;69(1):72-83. doi: 10.1111/his.12910. Epub 2016 Jan 19.PMID: 26647767

 

96. Histological spectrum of angiofibroma of soft tissue: histological and genetic analysis of 13 cases.

Yamada Y, Yamamoto H, Kohashi K, Ishii T, Iura K, Maekawa A, Bekki H, Otsuka H, Yamashita K, Tanaka H, Hiraki T, Mukai M, Shirakawa A, Shinnou Y, Jinno M, Yanai H, Taguchi K, Maehara Y, Iwamoto Y, Oda Y.

Histopathology. 2016 Sep;69(3):459-69. doi: 10.1111/his.12943. Epub 2016 Apr 1.PMID: 26845637

 

97. Reduced MUTYH, MTH1, and OGG1 expression and TP53 mutation in diffuse-type adenocarcinoma of gastric cardia.

Kohno Y, Yamamoto H, Hirahashi M, Kumagae Y, Nakamura M, Oki E, Oda Y.

Hum Pathol. 2016 Jun;52:145-52. doi: 10.1016/j.humpath.2016.01.006. Epub 2016 Feb 4.PMID: 26980051

 

98. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.

Nakano T, Yamamoto H, Nakashima T, Nishijima T, Satoh M, Hatanaka Y, Shiratsuchi H, Yasumatsu R, Toh S, Komune S, Oda Y.

Hum Pathol. 2016 Apr;50:51-61. doi: 10.1016/j.humpath.2015.11.001. Epub 2015 Nov 17.PMID: 26997438

 

99. Insulin-like growth factor II messenger RNA-binding protein-3 is an indicator of malignant phyllodes tumor of the breast.

Takizawa K, Yamamoto H, Taguchi K, Ohno S, Tokunaga E, Yamashita N, Kubo M, Nakamura M, Oda Y.

Hum Pathol. 2016 Sep;55:30-8. doi: 10.1016/j.humpath.2016.04.007. Epub 2016 Apr 29.PMID: 27137988

 

100. Reclassification of rhabdoid tumor and pediatric undifferentiated/unclassified sarcoma with complete loss of SMARCB1/INI1 protein expression: three subtypes of rhabdoid tumor according to their histological features.

Kohashi K, Tanaka Y, Kishimoto H, Yamamoto H, Yamada Y, Taguchi T, Iwamoto Y, Oda Y.

Mod Pathol. 2016 Oct;29(10):1232-42. doi: 10.1038/modpathol.2016.106. Epub 2016 Jun 22.PMID: 27338635

 

101. Phosphorylation of STAT3 in Undifferentiated Pleomorphic Sarcoma Is Correlated with a Favorable Prognosis.

Bekki H, Kohashi K, Yamada Y, Iura K, Ishii T, Maekawa A, Otsuka H, Yamamoto H, Hakozaki M, Nabeshima K, Iwamoto Y, Oda Y.

Pathobiology. 2017;84(3):161-169. doi: 10.1159/000448524. Epub 2016 Sep 22.PMID: 27652596

 

102. Duodenal Neoplasms of Gastric Phenotype: An Immunohistochemical and Genetic Study With a Practical Approach to the Classification.

Hida R, Yamamoto H, Hirahashi M, Kumagai R, Nishiyama K, Gi T, Esaki M, Kitazono T, Oda Y.

Am J Surg Pathol. 2017 Mar;41(3):343-353. doi: 10.1097/PAS.0000000000000785.PMID: 27984236

 

103. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.

Iura K, Maekawa A, Kohashi K, Ishii T, Bekki H, Otsuka H, Yamada Y, Yamamoto H, Harimaya K, Iwamoto Y, Oda Y.

Hum Pathol. 2017 Mar;61:130-139. doi: 10.1016/j.humpath.2016.12.006. Epub 2016 Dec 16.PMID: 27993576

 

104. Histological and immunohistochemical characteristics of undifferentiated small round cell sarcomas associated with CIC-DUX4 and BCOR-CCNB3 fusion genes.

Yamada Y, Kuda M, Kohashi K, Yamamoto H, Takemoto J, Ishii T, Iura K, Maekawa A, Bekki H, Ito T, Otsuka H, Kuroda M, Honda Y, Sumiyoshi S, Inoue T, Kinoshita N, Nishida A, Yamashita K, Ito I, Komune S, Taguchi T, Iwamoto Y, Oda Y.

Virchows Arch. 2017 Apr;470(4):373-380. doi: 10.1007/s00428-017-2072-8. Epub 2017 Feb 14.PMID: 28197724

 

105. Claudin 6 expression is useful to distinguish myxofibrosarcomas from other myxoid soft tissue tumors.

Bekki H, Yamamoto H, Takizawa K, Iwasaki T, Otsuka H, Yamada Y, Kohashi K, Harimaya K, Iwamoto Y, Oda Y.

Pathol Res Pract. 2017 Jun;213(6):674-679. doi: 10.1016/j.prp.2016.12.001. Epub 2016 Dec 5.PMID: 28476380

 

106. HIF-1α, MDM2, CDK4, and p16 expression in ischemic fasciitis, focusing on its ischemic condition.

Yamada Y, Kinoshita I, Kohashi K, Yamamoto H, Kuma Y, Ito T, Koda K, Kisanuki A, Kurosawa M, Yoshimura M, Furue M, Oda Y.

Virchows Arch. 2017 Jul;471(1):117-122. doi: 10.1007/s00428-017-2122-2. Epub 2017 May 6.PMID: 28477272

 

107. Comparison between retroperitoneal leiomyosarcoma and dedifferentiated liposarcoma.

Ishii T, Kohashi K, Ootsuka H, Iura K, Maekawa A, Yamada Y, Bekki H, Yoshimoto M, Yamamoto H, Iwamoto Y, Oda Y.

Pathol Res Pract. 2017 Jun;213(6):634-638. doi: 10.1016/j.prp.2017.04.022. Epub 2017 May 1.PMID: 28552535

 

108. Alteration of PDGFRβ-Akt-mTOR pathway signaling in fibrosarcomatous transformation of dermatofibrosarcoma protuberans.

Hiraki-Hotokebuchi Y, Yamada Y, Kohashi K, Yamamoto H, Endo M, Setsu N, Yuki K, Ito T, Iwamoto Y, Furue M, Oda Y.

Hum Pathol. 2017 Sep;67:60-68. doi: 10.1016/j.humpath.2017.07.001. Epub 2017 Jul 13.PMID: 28711648

 

109. MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1.

Iura K, Kohashi K, Ishii T, Maekawa A, Bekki H, Otsuka H, Yamada Y, Yamamoto H, Matsumoto Y, Iwamoto Y, Oda Y.

Virchows Arch. 2017 Sep;471(3):383-392. doi: 10.1007/s00428-017-2206-z. Epub 2017 Jul 26.PMID: 28744588

 

110. A novel fusion gene CRTC3-MAML2 in hidradenoma: histopathological significance.

Kuma Y, Yamada Y, Yamamoto H, Kohashi K, Ito T, Furue M, Oda Y.

Hum Pathol. 2017 Dec;70:55-61. doi: 10.1016/j.humpath.2017.10.004. Epub 2017 Oct 24.PMID: 29079171

 

111. Histopathological and genetic review of phosphaturic mesenchymal tumours, mixed connective tissue variant.

Yamada Y, Kinoshita I, Kenichi K, Yamamoto H, Iwasaki T, Otsuka H, Yoshimoto M, Ishihara S, Toda Y, Kuma Y, Setsu N, Koga Y, Honda Y, Inoue T, Yanai H, Yamashita K, Ito I, Takahashi M, Ohga S, Furue M, Nakashima Y, Oda Y.

Histopathology. 2018 Feb;72(3):460-471. doi: 10.1111/his.13377. Epub 2017 Nov 16.PMID: 28858396

 

112. Clinicopathologic and Molecular Characteristics of Synchronous Colorectal Carcinoma With Mismatch Repair Deficiency.

Nakano K, Yamamoto H, Fujiwara M, Koga Y, Tsuruta S, Ihara E, Oki E, Nakamura M, Ogawa Y, Oda Y.

Am J Surg Pathol. 2018 Feb;42(2):172-182. doi: 10.1097/PAS.0000000000000947.PMID: 28877066

 

113. Insulin-like growth factor II messenger RNA-binding protein-3 is an independent prognostic factor in uterine leiomyosarcoma.

Yasutake N, Ohishi Y, Taguchi K, Hiraki Y, Oya M, Oshiro Y, Mine M, Iwasaki T, Yamamoto H, Kohashi K, Sonoda K, Kato K, Oda Y.

Histopathology. 2018 Apr;72(5):739-748. doi: 10.1111/his.13422. Epub 2018 Jan 5.PMID: 29077232

 

114. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone.

Yamamoto H, Iwasaki T, Yamada Y, Matsumoto Y, Otsuka H, Yoshimoto M, Kohashi K, Taguchi K, Yokoyama R, Nakashima Y, Oda Y.

Hum Pathol. 2018 Mar;73:41-50. doi: 10.1016/j.humpath.2017.11.020. Epub 2017 Dec 12.PMID: 29241742

 

115. SWI/SNF Chromatin-remodeling Complex Status in SMARCB1/INI1-preserved Epithelioid Sarcoma.

Kohashi K, Yamamoto H, Yamada Y, Kinoshita I, Taguchi T, Iwamoto Y, Oda Y.

Am J Surg Pathol. 2018 Mar;42(3):312-318. doi: 10.1097/PAS.0000000000001011.PMID: 29309303

 

116. Cancer-testis antigens are predominantly expressed in uterine leiomyosarcoma compared with non-uterine leiomyosarcoma.

Iura K, Kohashi K, Yasutake N, Ishii T, Maekawa A, Bekki H, Otsuka H, Yamada Y, Yamamoto H, Ohishi Y, Matsumoto Y, Iwamoto Y, Oda Y.

Oncol Lett. 2018 Jan;15(1):441-446. doi: 10.3892/ol.2017.7274. Epub 2017 Oct 26.PMID: 29399140

 

117. Immunohistochemical evaluation of H3K27 trimethylation in malignant peripheral nerve sheath tumors.

Otsuka H, Kohashi K, Yoshimoto M, Ishihara S, Toda Y, Yamada Y, Yamamoto H, Nakashima Y, Oda Y.

Pathol Res Pract. 2018 Mar;214(3):417-425. doi: 10.1016/j.prp.2017.12.015. Epub 2018 Jan 31.PMID: 29482987

 

118. Wnt/β-catenin signal alteration and its diagnostic utility in basal cell adenoma and histologically similar tumors of the salivary gland.

Sato M, Yamamoto H, Hatanaka Y, Nishijima T, Jiromaru R, Yasumatsu R, Taguchi K, Masuda M, Nakagawa T, Oda Y.

Pathol Res Pract. 2018 Apr;214(4):586-592. doi: 10.1016/j.prp.2017.12.016. Epub 2018 Jan 3.PMID: 29496310

 

119. The expansion in lymphoid organs of IL-4+ BATF+ T follicular helper cells is linked to IgG4 class switching in vivo.

Maehara T, Mattoo H, Mahajan VS, Murphy SJ, Yuen GJ, Ishiguro N, Ohta M, Moriyama M, Saeki T, Yamamoto H, Yamauchi M, Daccache J, Kiyoshima T, Nakamura S, Stone JH, Pillai S.

Life Sci Alliance. 2018 Jan;1(1):e201800050. doi: 10.26508/lsa.201800050. Epub 2018 Apr 5.PMID: 29984361

 

120. Overexpression of MTH1 and OGG1 proteins in ulcerative colitis-associated carcinogenesis.

Kumagae Y, Hirahashi M, Takizawa K, Yamamoto H, Gushima M, Esaki M, Matsumoto T, Nakamura M, Kitazono T, Oda Y.

Oncol Lett. 2018 Aug;16(2):1765-1776. doi: 10.3892/ol.2018.8812. Epub 2018 May 25.PMID: 30008864

 

121. "Pancreatic Mucoepidermoid Carcinoma" Is not a Pancreatic Counterpart of CRTC1/3-MAML2 Fusion Gene-related Mucoepidermoid Carcinoma of the Salivary Gland, and May More Appropriately be Termed Pancreatic Adenosquamous Carcinoma With Mucoepidermoid Carcinoma-like Features.

Saeki K, Ohishi Y, Matsuda R, Mochidome N, Miyasaka Y, Yamamoto H, Koga Y, Maehara Y, Nakamura M, Oda Y.

Am J Surg Pathol. 2018 Nov;42(11):1419-1428. doi: 10.1097/PAS.0000000000001135.PMID: 30138216

 

122. Effects of menstrual cycle on background parenchymal enhancement and detectability of breast cancer on dynamic contrast-enhanced breast MRI: A multicenter study of an Asian population.

Kamitani T, Yabuuchi H, Kanemaki Y, Tozaki M, Sonomura T, Mizukoshi W, Nakata W, Shimono T, Urano M, Yamano T, Kato F, Kuchiki M, Shiragami N, Yanagita H, Katsuda E, Kataoka M, Yamaguchi K, Horikoshi T, Gomi T, Nozaki M, Shiotani M, Amano M, Saigusa H, Sadaoka S, Kamiya H, Kubo M, Yamashita N, Yamamoto H, Honda H.

Eur J Radiol. 2019 Jan;110:130-135. doi: 10.1016/j.ejrad.2018.11.025. Epub 2018 Nov 24.PMID: 30599849

 

123. Mucosal incision-assisted biopsy versus endoscopic ultrasound-guided fine-needle aspiration with a rapid on-site evaluation for gastric subepithelial lesions: A randomized cross-over study.

Osoegawa T, Minoda Y, Ihara E, Komori K, Aso A, Goto A, Itaba S, Ogino H, Nakamura K, Harada N, Makihara K, Tsuruta S, Yamamoto H, Ogawa Y.

Dig Endosc. 2019 Jul;31(4):413-421. doi: 10.1111/den.13367. Epub 2019 Apr 2.PMID: 30723945

 

124. Glypican-3 expression in malignant small round cell tumors.

Shibui Y, Miyoshi K, Kohashi K, Kinoshita Y, Kuda M, Yamamoto H, Taguchi T, Oda Y.

Oncol Lett. 2019 Mar;17(3):3523-3528. doi: 10.3892/ol.2019.9976. Epub 2019 Jan 25.PMID: 30867793

 

125. Endoscopic features of gastrointestinal stromal tumor in the small intestine.

Ihara Y, Torisu T, Moriyama T, Umeno J, Hirano A, Okamoto Y, Hori Y, Yamamoto H, Kitazono T, Esaki M.

Intest Res. 2019 Jul;17(3):398-403. doi: 10.5217/ir.2018.00161. Epub 2019 Jul 25.PMID: 31352775

 

126. Parotid gland carcinoma: 32 years' experience from a single institute.

Nakano T, Yasumatsu R, Kogo R, Hashimoto K, Asai K, Ohga S, Yamamoto H, Nakashima T, Nakagawa T.

J Laryngol Otol. 2019 Jul;133(7):604-609. doi: 10.1017/S0022215119001130. Epub 2019 Jun 6.

PMID: 31169091

 

127. Clinicopathological review of solitary fibrous tumors: dedifferentiation is a major cause of patient death.

Yamada Y, Kohashi K, Kinoshita I, Yamamoto H, Iwasaki T, Yoshimoto M, Ishihara S, Toda Y, Itou Y, Koga Y, Hashisako M, Nozaki Y, Kiyozawa D, Kitahara D, Inoue T, Mukai M, Honda Y, Toyokawa G, Tsuchihashi K, Matsushita Y, Fushimi F, Taguchi K, Tamiya S, Oshiro Y, Furue M, Nakashima Y, Suzuki S, Iwaki T, Oda Y.

Virchows Arch. 2019 Oct;475(4):467-477. doi: 10.1007/s00428-019-02622-9. Epub 2019 Aug 7.PMID: 31392468

 

128. Activated M2 Macrophages Contribute to the Pathogenesis of IgG4-Related Disease via Toll-like Receptor 7/Interleukin-33 Signaling.

Ishiguro N, Moriyama M, Furusho K, Furukawa S, Shibata T, Murakami Y, Chinju A, Haque ASMR, Gion Y, Ohta M, Maehara T, Tanaka A, Yamauchi M, Sakamoto M, Mochizuki K, Ono Y, Hayashida JN, Sato Y, Kiyoshima T, Yamamoto H, Miyake K, Nakamura S.

Arthritis Rheumatol. 2020 Jan;72(1):166-178. doi: 10.1002/art.41052. Epub 2019 Nov 29.PMID: 31339007

 

129. Diagnostic utility of pan-Trk immunohistochemistry for inflammatory myofibroblastic tumours.

Yamamoto H, Nozaki Y, Kohashi K, Kinoshita I, Oda Y.

Histopathology. 2020 Apr;76(5):774-778. doi: 10.1111/his.14010. Epub 2020 Mar 10.PMID: 31578734

 

130. Comparative Study of Myxofibrosarcoma With Undifferentiated Pleomorphic Sarcoma: Histopathologic and Clinicopathologic Review.

Yoshimoto M, Yamada Y, Ishihara S, Kohashi K, Toda Y, Ito Y, Yamamoto H, Furue M, Nakashima Y, Oda Y.

Am J Surg Pathol. 2020 Jan;44(1):87-97. doi: 10.1097/PAS.0000000000001389.PMID: 31651522

 

131. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.

Hori Y, Yamamoto H, Nozaki Y, Torisu T, Fujiwara M, Taguchi K, Nishiyama K, Nakamura S, Kitazono T, Oda Y.

Hum Pathol. 2020 Feb;96:67-78. doi: 10.1016/j.humpath.2019.09.003. Epub 2019 Nov 15.PMID: 31734190

 

132. HPV-related Sinonasal Carcinoma: Clinicopathologic Features, Diagnostic Utility of p16 and Rb Immunohistochemistry, and EGFR Copy Number Alteration.

Jiromaru R, Yamamoto H, Yasumatsu R, Hongo T, Nozaki Y, Hashimoto K, Taguchi K, Masuda M, Nakagawa T, Oda Y.

Am J Surg Pathol. 2020 Mar;44(3):305-315. doi: 10.1097/PAS.0000000000001410.PMID: 31743130

 

133. Central pathology review of salivary gland adenoid cystic carcinoma.

Ueda K, Murase T, Nagao T, Kusafuka K, Urano M, Yamamoto H, Nakaguro M, Taguchi KI, Masaki A, Hirai H, Kawakita D, Tsukahara K, Hato N, Nagao T, Fujimoto Y, Sakurai K, Hanai N, Kano S, Onitsuka T, Okami K, Nibu KI, Tada Y, Kawata R, Inagaki H.

Head Neck. 2020 Aug;42(8):1721-1727. doi: 10.1002/hed.26081. Epub 2020 Jan 23.PMID: 31970840

 

134. Helper T cell-dominant tertiary lymphoid structures are associated with disease relapse of advanced colorectal cancer.

Yamaguchi K, Ito M, Ohmura H, Hanamura F, Nakano M, Tsuchihashi K, Nagai S, Ariyama H, Kusaba H, Yamamoto H, Oda Y, Nakamura M, Akashi K, Baba E.

Oncoimmunology. 2020 Feb 17;9(1):1724763. doi: 10.1080/2162402X.2020.1724763. eCollection 2020.PMID: 32117589

 

135. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.

Toda Y, Kohashi K, Yamada Y, Yoshimoto M, Ishihara S, Ito Y, Iwasaki T, Yamamoto H, Matsumoto Y, Nakashima Y, Mawatari M, Oda Y.

J Cancer Res Clin Oncol. 2020 Oct;146(10):2607-2620. doi: 10.1007/s00432-020-03242-6. Epub 2020 May 9.PMID: 32388585

 

136. Amide proton transfer (APT) imaging of parotid tumors: Differentiation of malignant and benign tumors.

Kamitani T, Sagiyama K, Togao O, Yamasaki Y, Hida T, Matsuura Y, Murayama Y, Yasumatsu R, Yamamoto H, Yabuuchi H.

Eur J Radiol. 2020 Aug;129:109047. doi: 10.1016/j.ejrad.2020.109047. Epub 2020 May 21.PMID: 32460200

 

137. Chronic inflammatory changes and oxidative stress in the background of "pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm".

Matsuda R, Miyasaka Y, Yamada Y, Kawata J, Sakihama K, Yamamoto T, Saeki K, Yamamoto H, Ohishi Y, Koga Y, Nakamura M, Oda Y.

Virchows Arch. 2020 Dec;477(6):799-806. doi: 10.1007/s00428-020-02844-2. Epub 2020 May 28.PMID: 32468246

 

138. Genetic landscape of external auditory canal squamous cell carcinoma.

Sato K, Komune N, Hongo T, Koike K, Niida A, Uchi R, Noda T, Kogo R, Matsumoto N, Yamamoto H, Masuda M, Oda Y, Mimori K, Nakagawa T.

Cancer Sci. 2020 Aug;111(8):3010-3019. doi: 10.1111/cas.14515. Epub 2020 Jul 11.PMID: 32500594

 

139. Characterization of parotid gland tumors: added value of permeability MR imaging to DWI and DCE-MRI.

Yabuuchi H, Kamitani T, Sagiyama K, Yamasaki Y, Hida T, Matsuura Y, Hino T, Murayama Y, Yasumatsu R, Yamamoto H.

Eur Radiol. 2020 Dec;30(12):6402-6412. doi: 10.1007/s00330-020-07004-3. Epub 2020 Jul 1.PMID: 32613285

 

140. The impact of clinicopathological factors on clinical outcomes in patients with salivary gland adenoid cystic carcinoma: a multi-institutional analysis in Japan.

Kawakita D, Murase T, Ueda K, Kano S, Tada Y, Tsukahara K, Okami K, Onitsuka T, Fujimoto Y, Matoba T, Sakurai K, Nagao T, Hanai N, Kawata R, Hato N, Nibu KI, Urano M, Taguchi KI, Nakaguro M, Kusafuka K, Yamamoto H, Nagao T, Inagaki H.

Int J Clin Oncol. 2020 Oct;25(10):1774-1785. doi: 10.1007/s10147-020-01731-9. Epub 2020 Jul 1.PMID: 32613404

 

141. Prognostic impact of CRTC1/3-MAML2 fusions in salivary gland mucoepidermoid carcinoma: A multiinstitutional retrospective study.

Okumura Y, Nakano S, Murase T, Ueda K, Kawakita D, Nagao T, Kusafuka K, Urano M, Yamamoto H, Kano S, Tsukahara K, Okami K, Nagao T, Hanai N, Iwai H, Kawata R, Tada Y, Nibu KI, Inagaki H.

Cancer Sci. 2020 Nov;111(11):4195-4204. doi: 10.1111/cas.14632. Epub 2020 Sep 14.PMID: 32860299

 

142. Efficacy of endoscopic ultrasound with artificial intelligence for the diagnosis of gastrointestinal stromal tumors.

Minoda Y, Ihara E, Komori K, Ogino H, Otsuka Y, Chinen T, Tsuda Y, Ando K, Yamamoto H, Ogawa Y.

J Gastroenterol. 2020 Dec;55(12):1119-1126. doi: 10.1007/s00535-020-01725-4. Epub 2020 Sep 11.PMID: 32918102

 

143. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.

Nozaki Y, Yamamoto H, Iwasaki T, Sato M, Jiromaru R, Hongo T, Yasumatsu R, Oda Y.

Hum Pathol. 2020 Dec;106:82-92. doi: 10.1016/j.humpath.2020.09.004. Epub 2020 Sep 25.PMID: 32980422

 

144. Frequent MN1 Gene Mutations in Malignant Peripheral Nerve Sheath Tumor.

Kinoshita I, Yamada Y, Kohashi K, Yamamoto H, Iwasaki T, Ishihara S, Toda YU, Ito Y, Susuki Y, Kawaguchi K, Ichiki T, Sato Y, Furue M, Nakashima Y, Oda Y.

Anticancer Res. 2020 Nov;40(11):6221-6228. doi: 10.21873/anticanres.14642.PMID: 33109559

 

145. Clinicopathologic Significance of EGFR Mutation and HPV Infection in Sinonasal Squamous Cell Carcinoma.

Hongo T, Yamamoto H, Jiromaru R, Nozaki Y, Yasumatsu R, Hashimoto K, Yoneda R, Sugii A, Taguchi K, Masuda M, Nakagawa T, Oda Y.

Am J Surg Pathol. 2021 Jan;45(1):108-118. doi: 10.1097/PAS.0000000000001566.PMID: 32868526

 

146. B cell receptor signaling related to resistance to Helicobacter pylori eradication therapy in gastric diffuse large B cell lymphoma.

Torisu T, Kawano S, Miyawaki K, Yamamoto H, Ihara Y, Matsuno Y, Torisu K, Sugio T, Sasaki K, Shimakawa T, Kato K, Akashi K, Nakamura S, Kitazono T.

Hematol Oncol. 2021 Feb;39(1):145-147. doi: 10.1002/hon.2816. Epub 2020 Oct 14.PMID: 33034903

 

147. PD-L1 and IDO-1 expression in undifferentiated pleomorphic sarcoma: The associations with tumor infiltrating lymphocytes, dMMR and HLA class I.

Ishihara S, Yamada Y, Iwasaki T, Yoshimoto M, Toda Y, Kohashi K, Yamamoto H, Matsumoto Y, Nakashima Y, Oda Y.

Oncol Rep. 2021 Jan;45(1):379-389. doi: 10.3892/or.2020.7837. Epub 2020 Nov 5.PMID: 33155664

 

148. The forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in malignant rhabdoid tumor.

Shibui Y, Kohashi K, Tamaki A, Kinoshita I, Yamada Y, Yamamoto H, Taguchi T, Oda Y.

J Cancer Res Clin Oncol. 2021 May;147(5):1499-1518. doi: 10.1007/s00432-020-03438-w. Epub 2020 Nov 21.PMID: 33221995

 

149. Comprehensive molecular profiling broadens treatment options for breast cancer patients.

Kawaji H, Kubo M, Yamashita N, Yamamoto H, Kai M, Kajihara A, Yamada M, Kurata K, Kaneshiro K, Harada Y, Hayashi S, Shimazaki A, Mori H, Akiyoshi S, Oki E, Oda Y, Baba E, Mori M, Nakamura M.

Cancer Med. 2021 Jan;10(2):529-539. doi: 10.1002/cam4.3619. Epub 2020 Dec 4.PMID: 33274848

 

150. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.

Yamamoto H, Nozaki Y, Sugii A, Taguchi K, Hongo T, Jiromaru R, Sato M, Nakano T, Hashimoto K, Fujiwara M, Oda Y.

Hum Pathol. 2021 Mar;109:37-44. doi: 10.1016/j.humpath.2020.11.017. Epub 2020 Dec 7.PMID: 33301751

 

151. Pathological evaluation of tumor grade for salivary adenoid cystic carcinoma: A proposal of an objective grading system.

Morita N, Murase T, Ueda K, Nagao T, Kusafuka K, Nakaguro M, Urano M, Taguchi KI, Yamamoto H, Kano S, Tada Y, Tsukahara K, Okami K, Onitsuka T, Fujimoto Y, Kawakita D, Sakurai K, Nagao T, Hanai N, Kawata R, Hato N, Otsuki N, Nibu KI, Inagaki H.

Cancer Sci. 2021 Mar;112(3):1184-1195. doi: 10.1111/cas.14790. Epub 2021 Feb 2.PMID: 33377247

 

152. Genomic Sequencing of Cancer-related Genes in Sinonasal Squamous Cell Carcinoma and Coexisting Inverted Papilloma.

Uchi R, Jiromaru R, Yasumatsu R, Yamamoto H, Hongo T, Manako T, Sato K, Hashimoto K, Wakasaki T, Matsuo M, Nakagawa T.

Anticancer Res. 2021 Jan;41(1):71-79. doi: 10.21873/anticanres.14752.PMID: 33419800

 

153. Salivary Duct Carcinoma With Rhabdoid Features-No or Aberrant Expression of E-cadherin and Genetic Changes in CDH1: Immunohistochemical and Genetic Analyses of 17 Cases.

Kusafuka K, Yamada H, Ishino K, Maeda M, Yamanegi K, Baba S, Ohuchi T, Inagaki H, Yamamoto H, Iwasaki T, Tsuchiya C, Sugimura H, Suzuki M.

Am J Surg Pathol. 2021 Apr 1;45(4):439-449. doi: 10.1097/PAS.0000000000001672.PMID: 33538422

 

154. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.

Ishihara S, Iwasaki T, Kohashi K, Yamada Y, Toda Y, Ito Y, Susuki Y, Kawaguchi K, Takamatsu D, Kawatoko S, Kiyozawa D, Mori T, Kinoshita I, Yamamoto H, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Nakashima Y, Oda Y.

J Cancer Res Clin Oncol. 2021 Jul;147(7):2003-2011. doi: 10.1007/s00432-021-03616-4. Epub 2021 Apr 3.PMID: 33811537

 

155. p16 overexpression and Rb loss correlate with high-risk HPV infection in oropharyngeal squamous cell carcinoma.

Jiromaru R, Yamamoto H, Yasumatsu R, Hongo T, Nozaki Y, Nakano T, Hashimoto K, Nakagawa T, Oda Y.

Histopathology. 2021 Sep;79(3):358-369. doi: 10.1111/his.14337. Epub 2021 May 6.

PMID: 33450095

 

156. Brachyury expression in intracranial SMARCB1-deficient tumors: important points for distinguishing poorly differentiated chordoma from atypical teratoid/rhabdoid tumor.

Kohashi K, Yamamoto H, Yamada Y, Kinoshita I, Oda Y.

Hum Pathol. 2021 Jun;112:1-8. doi: 10.1016/j.humpath.2021.03.001. Epub 2021 Mar 17.

PMID: 33741347

 

157. Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.

Harada T, Iwasaki H, Muta T, Urata S, Sakamoto A, Kohno K, Takase K, Miyamura T, Sawabe T, Asaoku H, Oryoji K, Fujisaki T, Mori Y, Yoshimoto G, Ayano M, Mitoma H, Miyamoto T, Niiro H, Yamamoto H, Oshiro Y, Miyoshi H, Ohshima K, Takeshita M, Akashi K, Kato K.

Br J Haematol. 2021 Jul;194(1):101-110. doi: 10.1111/bjh.17456. Epub 2021 Apr 6.

PMID: 33822354

 

158. Myxoepithelioid tumour with chordoid features: a clinicopathological, immunohistochemical and genetic study of 14 cases of SMARCB1/INI1-deficient soft-tissue neoplasm.

Kinoshita I, Kohashi K, Yamamoto H, Yamada Y, Inoue T, Higaki K, Teramoto N, Oshiro Y, Nakashima Y, Oda Y.

Histopathology. 2021 Oct;79(4):629-641. doi: 10.1111/his.14393. Epub 2021 Jul 5.

PMID: 33932047

 

159. Programmed Death-Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Temporal Bone Squamous Cell Carcinoma.

Hongo T, Kuga R, Miyazaki M, Komune N, Nakano T, Yamamoto H, Koike K, Sato K, Kogo R, Nabeshima K, Oda Y, Nakagawa T.

Laryngoscope. 2021 Dec;131(12):2674-2683. doi: 10.1002/lary.29689. Epub 2021 Jun 18.

PMID: 34143491

 

160. PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma.

Hongo T, Yamamoto H, Jiromaru R, Yasumatsu R, Kuga R, Nozaki Y, Hashimoto K, Matsuo M, Wakasaki T, Tamae A, Taguchi K, Toh S, Masuda M, Nakagawa T, Oda Y.

Mod Pathol. 2021 Nov;34(11):1966-1978. doi: 10.1038/s41379-021-00868-w. Epub 2021 Jul 3.

PMID: 34218257

 

161. Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPalpha infiltration after denosumab treatment.

Toda Y, Kohashi K, Yamamoto H, Ishihara S, Ito Y, Susuki Y, Kawaguchi K, Kiyozawa D, Takamatsu D, Kinoshita I, Yamada Y, Maehara J, Kimura A, Tamiya S, Taguchi K, Matsunobu T, Matsumoto Y, Nakashima Y, Mawatari M, Oda Y.

Sci Rep. 2021 Jul 20;11(1):14821. doi: 10.1038/s41598-021-94022-w.

PMID: 34285260

 

162. Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 2+ Invasive Breast Cancer.

Yamada M, Kubo M, Yamamoto H, Yamashita N, Kai M, Zaguirre K, Kaneshiro K, Shimazaki A, Hayashi S, Kawaji H, Mori M, Oda Y, Nakamura M.

Anticancer Res. 2021 Aug;41(8):4143-4149. doi: 10.21873/anticanres.15217.

PMID: 34281885

 

163. Clinicopathological and prognostic significance of H3K27 methylation status in malignant peripheral nerve sheath tumor: correlation with skeletal muscle differentiation.

Ito Y, Kohashi K, Endo M, Yoshimoto M, Ishihara S, Toda Y, Susuki Y, Kawaguchi K, Furukawa H, Tateishi Y, Yamada Y, Kinoshita I, Mori T, Yamamoto H, Nakashima Y, Oda Y.

Virchows Arch. 2021 Dec;479(6):1233-1244. doi: 10.1007/s00428-021-03189-0. Epub 2021 Aug 25.

PMID: 34432163

 

164. Evaluation of MR imaging findings differentiating parotid basal cell adenomas from other parotid tumors.

Murayama Y, Kamitani T, Sagiyama K, Yamasaki Y, Hida T, Matsuura Y, Yasumatsu R, Yamamoto H, Yabuuchi H, Ishigami K.

Eur J Radiol. 2021 Nov;144:109980. doi: 10.1016/j.ejrad.2021.109980. Epub 2021 Sep 27.

PMID: 34601323

 

165. Pathological review of cardiac amyloidosis using autopsy cases in a single Japanese institution.

Tateishi Y, Yamada Y, Katsuki M, Nagata T, Yamamoto H, Kohashi K, Koga Y, Hashisako M, Kiyozawa D, Mori T, Kuboyama Y, Kakinokizono A, Miyazaki Y, Yamaguchi A, Tsutsui H, Ninomiya T, Naiki H, Oda Y.

Pathol Res Pract. 2021 Nov;227:153635. doi: 10.1016/j.prp.2021.153635. Epub 2021 Sep 28.

PMID: 34653913

 

166. Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?

Shimada E, Endo M, Matsumoto Y, Tsuchihashi K, Ito M, Kusaba H, Nabeshima A, Nawata T, Maekawa A, Matsunobu T, Setsu N, Fujiwara T, Iida K, Nakagawa M, Hirose T, Kanahori M, Oyama R, Isobe T, Ariyama H, Kohashi K, Yamamoto H, Oda Y, Iwamoto Y, Akashi K, Baba E, Nakashima Y.

J Clin Med. 2021 Oct 26;10(21):4972. doi: 10.3390/jcm10214972.

PMID: 34768491

 

167. Prognostic implication of desmoplastic stroma in synovial sarcoma: A histological review.

Toda Y, Yamada Y, Kohashi K, Ishihara S, Ito Y, Susuki Y, Kawaguchi K, Kinoshita I, Kiyozawa D, Mori T, Kuboyama Y, Tateishi Y, Yamamoto H, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Nakashima Y, Mawatari M, Oda Y.

Pathol Res Pract. 2021 Dec;228:153668. doi: 10.1016/j.prp.2021.153668. Epub 2021 Oct 26.

PMID: 34773915

 

168. A multi-institutional study of salivary gland cytopathology: Application of the Milan System for Reporting Salivary Gland Cytopathology in Japan.

Higuchi K, Urano M, Akiba J, Nogami M, Hirata Y, Zukeran Y, Moriyoshi K, Tada Y, Fukushima M, Obayashi M, Sakamoto S, Kuraoka K, Kira K, Kawahara A, Kato T, Tanigawa M, Nakaguro M, Yamamoto H, Nagao T.

Cancer Cytopathol. 2022 Jan;130(1):30-40. doi: 10.1002/cncy.22505. Epub 2021 Sep 3.

PMID: 34478237

 

169. Salivary mucoepidermoid carcinoma: histological variants, grading systems, CRTC1/3-MAML2 fusions, and clinicopathological features.

Nakano S, Okumura Y, Murase T, Nagao T, Kusafuka K, Urano M, Yamamoto H, Kano S, Tsukahara K, Okami K, Kawakita D, Nagao T, Hanai N, Iwai H, Kawata R, Tada Y, Nibu KI, Inagaki H.

Histopathology. 2022 Mar;80(4):729-735. doi: 10.1111/his.14586. Epub 2021 Dec 14.

PMID: 34657306

 

170. Clinicopathological and histopathological review of dedifferentiated liposarcoma: a comprehensive study of 123 primary tumours.

Mori T, Yamada Y, Kinoshita I, Kohashi K, Yamamoto H, Ito Y, Susuki Y, Kawaguchi K, Nakashima Y, Oda Y.

Histopathology. 2022 Feb;80(3):538-557. doi: 10.1111/his.14588. Epub 2021 Dec 14.

PMID: 34699612

 

171. An Analysis of 20 Cases of Radiation-Associated Sarcoma, Including 4 Cases Treated by Carbon Ion Radiotherapy.

Negishi T, Matsunobu A, Endo M, Yokoyama R, Kusano S, Furubayashi N, Taguchi K, Shioyama Y, Iida K, Fujiwara T, Setsu N, Matsumoto Y, Nakashima Y, Kohashi K, Yamamoto H, Oda Y, Nakamura M.

Oncology. 2022;100(3):148-154. doi: 10.1159/000521504. Epub 2021 Dec 16.

PMID: 34915507

 

172. Lymphoid and myeloid proliferative disorders associated with inflammatory bowel disease: A clinicopathological study of 15 cases.

Hori Y, Yamamoto H, Kawatoko S, Nozaki Y, Torisu T, Kato K, Koga Y, Miyoshi H, Ohshima K, Tateishi Y, Nakamura S, Kitazono T, Oda Y.

Hum Pathol. 2022 Jan 3:S0046-8177(21)00218-5. doi: 10.1016/j.humpath.2021.12.010.

Hum Pathol. 2022 Feb;120:88-98. doi: 10.1016/j.humpath.2021.12.010. Epub 2022 Jan 4.

PMID: 34990621

 

173. Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma.

Hashimoto K, Yasumatsu R, Kuga R, Hongo T, Yamamoto H, Matsuo M, Wakasaki T, Jiromaru R, Manako T, Toh S, Masuda M, Yamauchi M, Kuratomi Y, Uryu H, Nakashima T, Tamae A, Tanaka R, Taura M, Takeuchi T, Yoshida T, Nakagawa T.

Anticancer Res. 2022 Feb;42(2):981-989. doi: 10.21873/anticanres.15558.

PMID: 35093898

 

174. Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer.

Nakano T, Yasumatsu R, Hashimoto K, Kuga R, Hongo T, Yamamoto H, Matsuo M, Wakasaki T, Jiromaru R, Manako T, Toh S, Masuda M, Yamauchi M, Kuratomi Y, Uryu H, Nakashima T, Tamae A, Tanaka R, Taura M, Takeuchi T, Yoshida T, Nakagawa T.

In Vivo. 2022 Mar-Apr;36(2):979-984. doi: 10.21873/invivo.12790.

PMID: 35241559

 

175.

Histological background of dedifferentiated solitary fibrous tumour.

Yamada Y, Kohashi K, Kinoshita I, Yamamoto H, Iwasaki T, Yoshimoto M, Ishihara S, Toda Y, Ito Y, Kuma Y, Yamada-Nozaki Y, Koga Y, Hashisako M, Kiyozawa D, Kitahara D, Narutomi F, Kuboyama Y, Nakamura T, Inoue T, Mukai M, Honda Y, Toyokawa G, Tsuchihashi K, Fushimi F, Taguchi K, Nishiyama K, Tamiya S, Oshiro Y, Furue M, Nakashima Y, Suzuki S, Iwaki T, Oda Y.

J Clin Pathol. 2022 Jun;75(6):397-403. doi: 10.1136/jclinpath-2020-207311. Epub 2021 May 11.

PMID: 33975913

 

176.

Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation.

Ishihara S, Yamamoto H, Iwasaki T, Toda Y, Yamamoto T, Yoshimoto M, Ito Y, Susuki Y, Kawaguchi K, Kinoshita I, Yamada Y, Kohashi K, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Kakuda Y, Nakashima Y, Oda Y.

Mod Pathol. 2022 May;35(5):640-648. doi: 10.1038/s41379-021-00972-x. Epub 2021 Nov 16.

PMID: 34785767

 

177.

A clinical analysis of oropharyngeal squamous cell carcinoma: a single-institution's experience.

Jiromaru R, Yasumatsu R, Yamamoto H, Kuga R, Hongo T, Nakano T, Manako T, Hashimoto K, Wakasaki T, Matsuo M, Nakagawa T.

Eur Arch Otorhinolaryngol. 2022 Jul;279(7):3717-3725. doi: 10.1007/s00405-021-07236-z. Epub 2022 Jan 3.

PMID: 34978590

 

178.

High-risk HPV-related Squamous Cell Carcinoma in the Conjunctiva and Lacrimal sac: Clinicopathologic Characteristics and Diagnostic Utility of p16 and Rb Immunohistochemistry.

Hongo T, Yamamoto H, Tanabe M, Yasumatsu R, Kuga R, Miyazaki Y, Jiromaru R, Hashimoto K, Tateishi Y, Sonoda KH, Nakagawa T, Oda Y.

Am J Surg Pathol. 2022 Jul 1;46(7):977-987. doi: 10.1097/PAS.0000000000001857. Epub 2022 Jan 5.

PMID: 34985048

 

179.

Myxoid type and non-myxoid type of intimal sarcoma in large vessels and heart: review of histological and genetic profiles of 20 cases.

Yamada Y, Kinoshita I, Miyazaki Y, Tateishi Y, Kuboyama Y, Iwasaki T, Kohashi K, Yamamoto H, Ishihara S, Toda Y, Ito Y, Susuki Y, Kawaguchi K, Hashisako M, Yamada-Nozaki Y, Kiyozawa D, Mori T, Yamamoto T, Tsuchihashi K, Kuriwaki K, Mukai M, Kawai M, Suzuki K, Nishimura H, Bando K, Masumoto J, Fukushima M, Motoshita J, Mori H, Shiose A, Oda Y.

Virchows Arch. 2022 Apr;480(4):919-925. doi: 10.1007/s00428-022-03293-9. Epub 2022 Feb 16.

PMID: 35171325

 

180.

The implicated clinical factors for outcomes in 304 patients with salivary duct carcinoma: Multi-institutional retrospective analysis in Japan.

Kusafuka K, Sato Y, Nakatani E, Baba S, Maeda M, Yamanegi K, Ueda K, Inagaki H, Otsuki Y, Kuroda N, Suzuki K, Iwai H, Imamura Y, Itakura J, Yamanaka S, Takahashi H, Ito I, Akashi T, Daa T, Hamada M, Yasuda M, Kawata R, Yamamoto H, Tachibana Y, Fukuoka J, Muramatsu A, Arai K, Suzuki M.

Head Neck. 2022 Jun;44(6):1430-1441. doi: 10.1002/hed.27034. Epub 2022 Mar 29.

PMID: 35352425

 

181.

Clinical, Radiological, and Histopathological Characteristics of Periosteal Chondrosarcoma with a Focus on the Frequency of Medullary Invasion.

Nakagawa M, Endo M, Susuki Y, Yokoyama N, Maekawa A, Nabeshima A, Iida K, Fujiwara T, Setsu N, Matsunobu T, Matsumoto Y, Yokoyama R, Yamada Y, Kohashi K, Yamamoto H, Oda Y, Iwamoto Y, Nakashima Y.

J Clin Med. 2022 Apr 6;11(7):2062. doi: 10.3390/jcm11072062.

PMID: 35407670

 

182.

Distinct disease-specific Tfh cell populations in two different fibrotic diseases: IgG4-related disease and Kimura's disease.

Munemura R, Maehara T, Murakami Y, Koga R, Aoyagi R, Kaneko N, Doi A, Perugino CA, Della-Torre E, Saeki T, Sato Y, Yamamoto H, Kiyoshima T, Stone JH, Pillai S, Nakamura S.

J Allergy Clin Immunol. 2022 Aug;150(2):440-455.e17. doi: 10.1016/j.jaci.2022.03.034. Epub 2022 May 11.

PMID: 35568079

 

183.

Cyclin-dependent kinase 8 is an independent prognosticator in uterine leiomyosarcoma.

Yasutake N, Iwasaki T, Yamamoto H, Sonoda K, Kodama K, Okugawa K, Asanoma K, Yahata H, Kato K, Oda Y.

Pathol Res Pract. 2022 Jul;235:153920. doi: 10.1016/j.prp.2022.153920. Epub 2022 Apr 26.

PMID: 35605413

 

184.

Quantitative relaxometry using synthetic MRI could be better than T2-FLAIR mismatch sign for differentiation of IDH-mutant gliomas: a pilot study.

Kikuchi K, Togao O, Yamashita K, Momosaka D, Kikuchi Y, Kuga D, Hata N, Mizoguchi M, Yamamoto H, Iwaki T, Hiwatashi A, Ishigami K.

Sci Rep. 2022 Jun 2;12(1):9197. doi: 10.1038/s41598-022-13036-0.

PMID: 35654812

 

185.

Nuclear expression of AFF2 C-terminus is a sensitive and specific ancillary marker for DEK::AFF2 carcinoma of the sinonasal tract.

Kuo YJ, Lewis JS Jr, Truong T, Yeh YC, Chernock RD, Zhai C, Chen YA, Hongo T, Lee CK, Shi Q, Velez Torres JM, Geromes AB, Chu YH, Hsieh MS, Yamamoto H, Weinreb I, Hang JF.

Mod Pathol. 2022 Jun 14. doi: 10.1038/s41379-022-01117-4. Online ahead of print.

PMID: 35701667

 

186.

Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study.

Nakano T, Yasumatsu R, Hashimoto K, Kuga R, Hongo T, Yamamoto H, Matsuo M, Wakasaki T, Jiromaru R, Manako T, Toh S, Masuda M, Yamauchi M, Kuratomi Y, Taura M, Takeuchi T, Nakagawa T.

Anticancer Res. 2022 Jul;42(7):3653-3664. doi: 10.21873/anticanres.15854.

PMID: 35790253

 

187.

Negligible procedure-related dissemination risk of mucosal incision-assisted biopsy for gastrointestinal stromal tumors versus endoscopic ultrasound-guided fine-needle aspiration/biopsy.

Minoda Y, Ihara E, Itaba S, Sumida Y, Haraguchi K, Aso A, Mizutani T, Osoegawa T, Esaki M, Nagatomo S, Nishioka K, Muta K, Bai X, Ogino H, Fujimori N, Tsurumaru D, Ohuchida K, Qingjiang H, Oki E, Yamamoto H, Ogawa Y.

Surg Endosc. 2022 Jul 15. doi: 10.1007/s00464-022-09419-z. Online ahead of print.

PMID: 35840712

 

188.

Salivary Gland Polymorphous Adenocarcinoma: Clinicopathological Features and Gene Alterations in 36 Japanese Patients.

Fukumura M, Ishibashi K, Nakaguro M, Nagao T, Saida K, Urano M, Tanigawa M, Hirai H, Yagyuu T, Kikuchi K, Yada N, Sugita Y, Miyabe M, Hasegawa S, Goto M, Yamamoto H, Ohuchi T, Kusafuka K, Ogawa I, Suzuki H, Notohara K, Shimoda M, Tada Y, Kirita T, Takata T, Morinaga S, Maeda H, Warnakulasuriya S, Miyabe S, Nagao T.

J Oral Pathol Med. 2022 Jul 26. doi: 10.1111/jop.13336. Online ahead of print.

PMID: 35880805

 

189.

Nuclear β-catenin translocation plays a key role in osteoblast differentiation of giant cell tumor of bone.

Kimura A, Toda Y, Matsumoto Y, Yamamoto H, Yahiro K, Shimada E, Kanahori M, Oyama R, Fukushima S, Nakagawa M, Setsu N, Endo M, Fujiwara T, Matsunobu T, Oda Y, Nakashima Y.

Sci Rep. 2022 Aug 4;12(1):13438. doi: 10.1038/s41598-022-17728-5.

PMID: 35927428